JP2024546106A5 - - Google Patents

Info

Publication number
JP2024546106A5
JP2024546106A5 JP2024534244A JP2024534244A JP2024546106A5 JP 2024546106 A5 JP2024546106 A5 JP 2024546106A5 JP 2024534244 A JP2024534244 A JP 2024534244A JP 2024534244 A JP2024534244 A JP 2024534244A JP 2024546106 A5 JP2024546106 A5 JP 2024546106A5
Authority
JP
Japan
Prior art keywords
dlk1
antigen
antibody
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/052135 external-priority patent/WO2023107560A1/en
Publication of JP2024546106A publication Critical patent/JP2024546106A/ja
Publication of JP2024546106A5 publication Critical patent/JP2024546106A5/ja
Pending legal-status Critical Current

Links

JP2024534244A 2021-12-07 2022-12-07 Ｄｌｋ１抗体及びがんを処置する方法 Pending JP2024546106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163286896P 2021-12-07 2021-12-07
US63/286,896 2021-12-07
PCT/US2022/052135 WO2023107560A1 (en) 2021-12-07 2022-12-07 Dlk1 antibodies and methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2024546106A JP2024546106A (ja) 2024-12-17
JP2024546106A5 true JP2024546106A5 (https=) 2026-01-14

Family

ID=86731155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534244A Pending JP2024546106A (ja) 2021-12-07 2022-12-07 Ｄｌｋ１抗体及びがんを処置する方法

Country Status (10)

Country Link
US (1) US20250042992A1 (https=)
EP (1) EP4444350A4 (https=)
JP (1) JP2024546106A (https=)
KR (1) KR20240130094A (https=)
CN (1) CN119486755A (https=)
AU (1) AU2022408069A1 (https=)
CA (1) CA3240297A1 (https=)
IL (1) IL313298A (https=)
MX (1) MX2024006969A (https=)
WO (1) WO2023107560A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120737193B (zh) * 2025-09-03 2025-12-16 中山大学 一种抗Oya病毒核衣壳蛋白的单克隆抗体或其抗原结合片段及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101512203B1 (ko) * 2006-11-10 2015-04-15 가부시키가이샤 리부텍쿠 ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
US8017118B2 (en) * 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
DK2421898T3 (en) * 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
WO2014093379A1 (en) * 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
AU2016359235B2 (en) * 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
KR102503143B1 (ko) * 2019-03-06 2023-02-24 주식회사 레고켐 바이오사이언스 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Similar Documents

Publication Publication Date Title
KR102777693B1 (ko) Claudin18 항체 및 암 치료 방법
JP2025503402A5 (https=)
JP7682797B2 (ja) クローディン６二重特異性抗体
US20250051437A1 (en) Cdh17 antibodies and methods of treating cancer
US12065489B2 (en) Claudin-6 antibodies and drug conjugates
JP2024546106A5 (https=)
JP2024546106A (ja) Ｄｌｋ１抗体及びがんを処置する方法
HK40125763A (en) Claudin-6 antibodies and drug conjugates
WO2025106822A2 (en) P2ry8 antibodies and methods of treating cancer
AU2024379016A1 (en) P2ry8 antibodies and methods of treating cancer
HK40067893A (en) Claudin-6 antibodies and drug conjugates
HK40067893B (en) Claudin-6 antibodies and drug conjugates